SUPN Supernus Pharmaceuticals, Inc.

34.15
-0.40  -1%
Previous Close 34.55
Open 34.75
Price To book 8.42
Market Cap 1.72B
Shares 50,282,000
Volume 475,192
Short Ratio 3.68
Av. Daily Volume 616,581

SEC filingsSee all SEC filings

  1. 10-Q - Quarterly report [Sections 13 or 15(d)] 17827537
  2. 8-K - Current report 17827038
  3. DEF 14A - Other definitive proxy statements 17789690
  4. 8-K - Current report 17784914
  5. 8-K - Current report 17756378

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approved October 22, 2017.
Oxtellar
Epilepsy
Phase 2b trial met primary endpoint - October 11, 2016. Phase 3 planned for 2H 2017.
SPN-812
ADHD
Phase 3 enrollment to continue through to 2017.
SPN-810
Impulsive Aggression in ADHD
Approved Aug 19, 2013.
Trokendi
Epilepsy
Tentative approval August 19 2016, subject to the pediatric exclusivity which expires March 28, 2017. Final approval announced April 6, 2017.
Trokendi
Migraine